First Horizon Advisors Inc. Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

First Horizon Advisors Inc. purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 4,765 shares of the company’s stock, valued at approximately $47,000.

Other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. increased its position in shares of Recursion Pharmaceuticals by 34.1% in the fourth quarter. Victory Capital Management Inc. now owns 20,441 shares of the company’s stock worth $202,000 after purchasing an additional 5,195 shares during the period. New York State Common Retirement Fund increased its position in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. New York State Common Retirement Fund now owns 58,414 shares of the company’s stock worth $576,000 after purchasing an additional 10,177 shares during the period. Handelsbanken Fonder AB increased its position in shares of Recursion Pharmaceuticals by 52.2% in the fourth quarter. Handelsbanken Fonder AB now owns 34,100 shares of the company’s stock worth $336,000 after purchasing an additional 11,700 shares during the period. Daiwa Securities Group Inc. increased its position in shares of Recursion Pharmaceuticals by 1,508.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 11,759 shares of the company’s stock worth $116,000 after purchasing an additional 11,028 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Recursion Pharmaceuticals by 32.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 40,658 shares of the company’s stock valued at $401,000 after acquiring an additional 10,033 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $8.59 on Thursday. The stock’s 50-day simple moving average is $9.63 and its 200 day simple moving average is $9.26. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -5.54 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.92 and a 52-week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on RXRX. KeyCorp lifted their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. TD Cowen began coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a “market perform” rating on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.75.

Insider Transactions at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the transaction, the chief executive officer now owns 863,524 shares of the company’s stock, valued at $6,675,040.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Tina Marriott sold 8,000 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total transaction of $119,120.00. Following the transaction, the chief operating officer now directly owns 639,982 shares of the company’s stock, valued at $9,529,331.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the sale, the chief executive officer now directly owns 863,524 shares in the company, valued at $6,675,040.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 352,946 shares of company stock valued at $3,485,453. Insiders own 15.75% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.